Treatment of hepatitis C: Results in real life

Abstract

Chronic hepatitis C virus (HCV) is a serious infection affecting approx K E Y W O R D Sdirect-acting antiviral, hepatitis C, real-world, sustained virological response

Real‐world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C‐Registry

“…There are limited real‐world data on glecaprevir/pibrentasvir to date . Real‐world data are crucial for understanding treatment effectiveness and safety in everyday clinical practice, particularly in patient populations that may be excluded from or under‐represented in clinical trials, such as patients with substance abuse disorders . The aim of this study was to evaluate the effectiveness and safety of glecaprevir/pibrentasvir under real‐world conditions in adult patients with chronic HCV infection enrolled in the German Hepatitis C‐Registry (Deutsches Hepatitis C‐Register, DHC‐R).…”

Effectiveness and safety of sofosbuvir‐based therapy against chronic hepatitis C infection after successful kidney transplantation

“…DAAs are safe for use in patients with decompensated liver cirrhosis accompanied by immunological complications of HCV infection and after liver transplantation. The efficacy of DAA therapies in these patients is regularly reported as greater than 85%–90% . After solid organ transplantation, especially the kidney or liver, patients may have to wait for years to start anti‐HCV therapy as interferon‐based therapies are not routinely recommended because of the possibility of interferon‐induced acute kidney graft rejection, which reportedly occurs in 15%–64% of such cases .…”

“…patients is regularly reported as greater than 85%-90%. 1,2 After solid organ transplantation, especially the kidney or liver, patients may have to wait for years to start anti-HCV therapy as interferon-based therapies are not routinely recommended because of the possibility of interferon-induced acute kidney graft rejection, which reportedly occurs in 15%-64% of such cases. [3][4][5] However, individual cost-benefit assessments are recommended for patients with recurrent, HCV-mediated, kidney graft glomerulonephritis, and those with advanced liver disease, such as bridging fibrosis or cirrhosis.…”

Leaving behind pegylated interferon‐based regimens to eliminate hepatitis C as a public health threat by 2030 as set out by WHO

“…The impact of late presentation on the prognosis of chronic HCV infection remains unknown, its elucidation is a priority of ongoing research and policy involving health systems organization. However, advanced liver disease is no longer a contraindication to HCV therapy, as excellent SVR rates have been reported . Nevertheless, there is a 10%‐15% reduction in the efficacy of regimens in those with decompensated disease and given the higher risk of hepatocellular carcinoma (HCC) associated with cirrhosis, it is still incumbent to aspire for early testing and linkage to care, even in settings where DAAs are available without restriction.…”